bioMerieux (BIM) Stock Forecast & Price Target

Compare

7 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

BIM Analyst Ratings

Strong Buy

3 Buy

1 Hold

0 Sell

Based on 4 analysts giving stock ratings to

bioMerieux

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

BIM Stock 12 Month Forecast

Average Price Target

€131.00

▲(7.38%Upside)

Based on 4 Wall Street analysts offering 12 month price targets for bioMerieux in the last 3 months. The average price target is €131.00 with a high forecast of €140.00 and a low forecast of €125.00. The average price target represents a 7.38% change from the last price of €122.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"88":"€88","141":"€141","101.25":"€101.3","114.5":"€114.5","127.75":"€127.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":140,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€140.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":131,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€131.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":125,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€125.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[88,101.25,114.5,127.75,141],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,118.7,120.33846153846154,121.97692307692309,123.61538461538461,125.25384615384615,126.8923076923077,128.53076923076924,130.16923076923078,131.80769230769232,133.44615384615383,135.08461538461538,136.72307692307692,138.36153846153846,{"y":140,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,118.7,119.64615384615385,120.5923076923077,121.53846153846155,122.48461538461538,123.43076923076923,124.37692307692308,125.32307692307693,126.26923076923077,127.21538461538462,128.16153846153847,129.1076923076923,130.05384615384617,{"y":131,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,118.7,119.18461538461538,119.66923076923077,120.15384615384616,120.63846153846154,121.12307692307692,121.6076923076923,122.0923076923077,122.57692307692308,123.06153846153846,123.54615384615384,124.03076923076924,124.51538461538462,{"y":125,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":101.092,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.109,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":89.7,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":98.1,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.4,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":108.9,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.5,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":97.5,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.5,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":117.1,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":115.5,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":115.5,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":118.7,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€140.00

Average Price Target€131.00

Lowest Price Target€125.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Natalia WebsterRBC Capital

RBC Capital

€125

Hold

2.46%

Upside

Reiterated

05/28/25

RBC Capital Sticks to Their Hold Rating for bioMerieux (0RUG)

Kavya DeshpandeUBS

UBS

€138→€132

Buy

8.20%

Upside

Reiterated

04/25/25

BioMerieux (BIM:FP) (BMXMF) PT Lowered to EUR132 at UBSUBS analyst Kavya Deshpande lowered the price target on BioMerieux (BIM:FP) (OTC: BMXMF) to EUR132.00 (from EUR138.00) while maintaining a Buy rating.

Aisyah NoorMorgan Stanley

Morgan Stanley

€129→€127

Buy

4.10%

Upside

Reiterated

04/18/25

BioMerieux (BIM:FP) (BMXMF) PT Lowered to EUR127 at Morgan StanleyMorgan Stanley analyst Aisyah Noor lowered the price target on BioMerieux (BIM:FP) (OTC: BMXMF) to EUR127.00 (from EUR129.00) while maintaining a Overweight rating.

Maja PatakiKepler Capital

Kepler Capital

€140

Buy

14.75%

Upside

Reiterated

04/17/25

Kepler Capital Keeps Their Buy Rating on bioMerieux (0RUG)

Jan KochDeutsche Bank

Deutsche Bank

€130→€132

Buy

8.20%

Upside

Reiterated

02/17/25

BioMerieux (BIM:FP) (BMXMF) PT Raised to EUR132 at Deutsche BankDeutsche Bank analyst Jan Koch raised the price target on BioMerieux (BIM:FP) (OTC: BMXMF) to EUR132.00 (from EUR130.00) while maintaining a Buy rating.

Gaurav JainBarclays

Barclays

€120→€132

Buy

8.20%

Upside

Reiterated

02/06/25

BioMerieux (BIM:FP) (BMXMF) PT Raised to EUR132 at BarclaysBarclays analyst Gaurav Jain raised the price target on BioMerieux (BIM:FP) (OTC: BMXMF) to EUR132.00 (from EUR120.00) while maintaining a Overweight rating.

Dylan Van HaaftenStifel Nicolaus

Stifel Nicolaus

€124

Buy

1.64%

Upside

Reiterated

10/30/24

Strong Q3 Performance and Strategic Positioning Lead to Buy Rating for bioMerieux

Shubhangi GuptaHSBC

HSBC

€120→€126

Buy

3.28%

Upside

Reiterated

10/17/24

BioMerieux (BIM:FP) (BMXMF) PT Raised to EUR126 at HSBCHSBC analyst Shubhangi Gupta raised the price target on BioMerieux (BIM:FP) (OTC: BMXMF) to EUR126.00 (from EUR120.00) while maintaining a Buy rating.

Odysseas ManesiotisExane BNP Paribas

Exane BNP Paribas

€122.2

Buy

0.16%

Upside

Reiterated

09/10/24

Berenberg Bank Keeps Their Buy Rating on bioMerieux (0RUG)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Natalia WebsterRBC Capital

RBC Capital

€125

Hold

2.46%

Upside

Reiterated

05/28/25

RBC Capital Sticks to Their Hold Rating for bioMerieux (0RUG)

Kavya DeshpandeUBS

UBS

€138→€132

Buy

8.20%

Upside

Reiterated

04/25/25

Aisyah NoorMorgan Stanley

Morgan Stanley

€129→€127

Buy

4.10%

Upside

Reiterated

04/18/25

Maja PatakiKepler Capital

Kepler Capital

€140

Buy

14.75%

Upside

Reiterated

04/17/25

Kepler Capital Keeps Their Buy Rating on bioMerieux (0RUG)

Jan KochDeutsche Bank

Deutsche Bank

€130→€132

Buy

8.20%

Upside

Reiterated

02/17/25

Gaurav JainBarclays

Barclays

€120→€132

Buy

8.20%

Upside

Reiterated

02/06/25

Dylan Van HaaftenStifel Nicolaus

Stifel Nicolaus

€124

Buy

1.64%

Upside

Reiterated

10/30/24

Strong Q3 Performance and Strategic Positioning Lead to Buy Rating for bioMerieux

Shubhangi GuptaHSBC

HSBC

€120→€126

Buy

3.28%

Upside

Reiterated

10/17/24

Odysseas ManesiotisExane BNP Paribas

Exane BNP Paribas

€122.2

Buy

0.16%

Upside

Reiterated

09/10/24

Berenberg Bank Keeps Their Buy Rating on bioMerieux (0RUG)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering bioMerieux

1 Month

xxx

Success Rate

4/7 ratings generated profit

Average Return

-0.03%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 57.14% of your transactions generating a profit, with an average return of -0.03% per trade.

3 Months

xxx

Success Rate

5/7 ratings generated profit

Average Return

+2.91%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 71.43% of your transactions generating a profit, with an average return of +2.91% per trade.

1 Year

Kavya DeshpandeUBS

Success Rate

7/7 ratings generated profit

Average Return

+12.80%

reiterated a buy rating last month

Copying Kavya Deshpande's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +12.80% per trade.

2 Years

xxx

Success Rate

7/7 ratings generated profit

Average Return

+12.80%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +12.80% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BIM Analyst Recommendation Trends

Rating

Jan 25

Feb 25

Mar 25

Apr 25

May 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, BIM has received 7 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. BIM average Analyst price target in the past 3 months is 131.00.

Each month's total comprises the sum of three months' worth of ratings.

BIM Financial Forecast

BIM Earnings Forecast

Next quarter’s earnings estimate for BIM is €2.11 with a range of €2.11 to €2.11. The previous quarter’s EPS was €1.84. BIM beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year BIM has Preformed in-line its overall industry.

BIM Sales Forecast

Next quarter’s sales forecast for BIM is €973.50M with a range of €966.00M to €981.00M. The previous quarter’s sales results were €2.08B. BIM beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.56% of the time in the same period. In the last calendar year BIM has Outperformed its overall industry.

BIM Stock Forecast FAQ

What is FR:BIM’s average 12-month price target, according to analysts?

Based on analyst ratings, bioMerieux SA’s 12-month average price target is 131.00.

What is FR:BIM’s upside potential, based on the analysts’ average price target?

bioMerieux SA has 7.38% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is bioMerieux SA a Buy, Sell or Hold?

bioMerieux SA has a consensus rating of Strong Buy, which is based on 3 buy ratings, 1 hold ratings and 0 sell ratings.

What is bioMerieux SA’s share price target?

The average share price target for bioMerieux SA is 131.00. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €140.00 ,and the lowest forecast is €125.00. The average share price target represents 7.38% Increase from the current price of €122.

What do analysts say about bioMerieux SA?

bioMerieux SA’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.

How can I buy shares of bioMerieux SA?

To buy shares of FR:BIM, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

bioMerieux (BIM) Stock Forecast & Price Target

BIM Analyst Ratings

BIM Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering bioMerieux

BIM Analyst Recommendation Trends

BIM Financial Forecast

BIM Earnings Forecast

BIM Sales Forecast

BIM Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts